AU1103699A - Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia - Google Patents

Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia

Info

Publication number
AU1103699A
AU1103699A AU11036/99A AU1103699A AU1103699A AU 1103699 A AU1103699 A AU 1103699A AU 11036/99 A AU11036/99 A AU 11036/99A AU 1103699 A AU1103699 A AU 1103699A AU 1103699 A AU1103699 A AU 1103699A
Authority
AU
Australia
Prior art keywords
darpp
dephosphorylation
inhibitor
use
treating schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11036/99A
Inventor
Allen A. FIENBERG
Paul Greengard
Akinori Nishi
Gretchen L. Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08953442 priority Critical
Priority to US08/953,442 priority patent/US6013621A/en
Priority to US17401598A priority
Priority to US09174015 priority
Application filed by Rockefeller University filed Critical Rockefeller University
Priority to PCT/US1998/022127 priority patent/WO1999020273A1/en
Publication of AU1103699A publication Critical patent/AU1103699A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/30Psychoses; Psychiatry
    • G01N2800/302Schizophrenia
AU11036/99A 1997-10-17 1998-10-19 Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia Abandoned AU1103699A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US08953442 1997-10-17
US08/953,442 US6013621A (en) 1997-10-17 1997-10-17 Method of treating psychosis and/or hyperactivity
US17401598A true 1998-10-16 1998-10-16
US09174015 1998-10-16
PCT/US1998/022127 WO1999020273A1 (en) 1997-10-17 1998-10-19 Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia

Publications (1)

Publication Number Publication Date
AU1103699A true AU1103699A (en) 1999-05-10

Family

ID=26869782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11036/99A Abandoned AU1103699A (en) 1997-10-17 1998-10-19 Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia

Country Status (2)

Country Link
AU (1) AU1103699A (en)
WO (1) WO1999020273A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989362B1 (en) 1999-10-15 2006-01-24 The Rockefeller University Methods of treating dopamine dysregulation using agents that regulate phosphorylation/dephosphorylation in dopamine signaling
WO2003020702A2 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
CA2458968A1 (en) 2001-08-31 2003-03-13 The Rockefeller University Method for classification of anti-psychotic drugs
EP1578354A4 (en) * 2002-03-26 2008-04-09 Massachusetts Inst Technology Targets, methods, and reagents for diagnosis and treatment of schizophrenia
WO2005113572A2 (en) * 2004-05-19 2005-12-01 Merck & Co., Inc. Isolated nucleic acid molecules encoding a novel phosphoprotein-darpp-32, encoded protein and uses thereof
EP2461673A4 (en) 2009-08-05 2013-08-07 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110011A (en) * 1994-06-13 2004-09-27 Yeda Res & Dev Pharmaceutical compositions for the treatment of schizophrenia
US5777195A (en) * 1996-05-17 1998-07-07 The Rockefeller University Knockout mutant mouse for DARPP-32 and use thereof

Also Published As

Publication number Publication date
WO1999020273A1 (en) 1999-04-29

Similar Documents

Publication Publication Date Title
AU698911B2 (en) Thrombin inhibitors
AU676884B2 (en) 1H-indole-3-acetamide sPLA2 inhibitors
DE69531753T2 (en) Compounds for the inhibition of thrombin
AU684007B2 (en) Chimeric complement inhibitor proteins
AU688952B2 (en) Thrombin inhibitors
AU4315699A (en) Apparatus for providing coronary retroperfusion and methods of use
AU5533094A (en) Enzyme inhibitors
AU1118097A (en) Protease inhibitors
IL128662D0 (en) Heterocyclic metalloprotease inhibitors
AU5231598A (en) Triarylethanes useful as pde iv inhibitors
AU6344996A (en) System for the plasma treatment of large area substrates
AU2001284192A1 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
AU2114495A (en) An absorbent article
AU2805897A (en) Inhibitors of protein farnesyltransferase
AU2152195A (en) An absorbent article
AU4088297A (en) Inhibitors of phospholipase enzymes
IN190508B (en) Inhibitors or impdh enzyme and process for preparation of the same
AU1433299A (en) Disinfecting agent
AU6701598A (en) Inhibitors of impdh enzyme
AU1054897A (en) Protein kinase c inhibitor
AU4267293A (en) Use of MMP inhibitors
NZ288591A (en) Inhibitors of thrombin
AU8495198A (en) Water-stabilized organosilane compounds and methods for using the same
AU2746695A (en) Metalloproteinase inhibitors
AU1459795A (en) Metalloproteinase inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase